Tao Tianqi, He Tao, Wang Xiaoreng, Liu Xiuhua
Department of Pathophysiology, Chinese PLA General Hospital, Beijing, China.
Front Pharmacol. 2019 Sep 10;10:985. doi: 10.3389/fphar.2019.00985. eCollection 2019.
Coronary heart disease (CHD) remains the leading cause of morbidity and mortality worldwide. Traditional Chinese medicine (TCM) is one of the effective complementary and alternative therapies used to improve the prognosis of CHD patients. Xuefu Zhuyu (XFZY) decoction, a classical traditional Chinese medication for regulating Qi and promoting blood circulation, has a clinical benefit in CHD; however, the underlying mechanism is not clear. Recently, it was found that the metabolites involved in amino acid metabolism and the tricarboxylic acid cycle were altered in CHD patients with Qi and Yin deficiency syndrome. To understand the material foundation of Qi, it is of great significance to study the differential metabolites involved in Qi during treatment of CHD with Qi-regulating and blood-promoting herbs. In this study, we investigated the metabolic profiles of serum in CHD patients by nontargeted metabolomics analysis to detect differential metabolites between the XFZY decoction group and placebo group. Ten CHD patients were enrolled and treated with placebo granules or XFZY decoction granules in a random and double-blind manner. Serum samples of all patients were evaluated by untargeted high-performance liquid chromatography with tandem mass spectrometry-based metabolomics. In total, 513 metabolites were detected in the serum of CHD patients, and six of these metabolites participating in seven metabolic pathways were significantly different between CHD patients treated with XFZY decoction and the placebo group. Among the six differential metabolites, FA (20:2)-H and tetracarboxylic acid (24:0), involved in fatty acid metabolism; cis-aconitic acid, which participates in the tricarboxylic acid cycle; 2-deoxy-D-glucose, involved in glucose metabolism; and N-acetylglycine, involved in amino acid metabolism, were decreased, whereas spermine, which participates in amino acid metabolism, was increased as compared with the placebo group. Our findings, combined with the perspective of biological functions, indicate that 2-deoxy-D-glucose and spermine might constitute the partial material foundation of Qi in CHD patients treated with XFZY decoction.
冠心病(CHD)仍是全球发病和死亡的主要原因。中医是用于改善冠心病患者预后的有效补充和替代疗法之一。血府逐瘀(XFZY)汤是一种调节气血的经典中药方剂,对冠心病有临床疗效;然而,其潜在机制尚不清楚。最近发现,气阴两虚证冠心病患者中参与氨基酸代谢和三羧酸循环的代谢物发生了改变。为了解气的物质基础,研究理气活血中药治疗冠心病过程中与气相关的差异代谢物具有重要意义。在本研究中,我们通过非靶向代谢组学分析研究了冠心病患者血清的代谢谱,以检测XFZY汤组和安慰剂组之间的差异代谢物。招募了10名冠心病患者,以随机双盲方式给予安慰剂颗粒或XFZY汤颗粒治疗。所有患者的血清样本通过基于非靶向高效液相色谱-串联质谱的代谢组学进行评估。在冠心病患者血清中共检测到513种代谢物,其中参与7条代谢途径的6种代谢物在接受XFZY汤治疗的冠心病患者和安慰剂组之间存在显著差异。在这6种差异代谢物中,参与脂肪酸代谢的FA(20:2)-H和二十四烷酸、参与三羧酸循环的顺乌头酸、参与葡萄糖代谢的2-脱氧-D-葡萄糖以及参与氨基酸代谢的N-乙酰甘氨酸与安慰剂组相比减少,而参与氨基酸代谢的精胺增加。我们的研究结果结合生物学功能的观点表明,2-脱氧-D-葡萄糖和精胺可能构成XFZY汤治疗冠心病患者中气的部分物质基础。